BiondVax Pharmaceuticals (NASDAQ:BVXV) Coverage Initiated at started coverage on shares of BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) in a report published on Monday. The firm issued a sell rating on the stock.

BiondVax Pharmaceuticals Trading Up 0.9 %

BiondVax Pharmaceuticals stock opened at $0.93 on Monday. BiondVax Pharmaceuticals has a 52 week low of $0.53 and a 52 week high of $3.49. The company has a debt-to-equity ratio of 11.62, a quick ratio of 1.71 and a current ratio of 1.71. The firm has a market capitalization of $13.34 million, a price-to-earnings ratio of -1.53 and a beta of 2.36. The company has a 50 day moving average price of $0.81 and a 200 day moving average price of $1.07.

BiondVax Pharmaceuticals (NASDAQ:BVXVGet Rating) last posted its quarterly earnings results on Thursday, August 25th. The company reported ($0.21) earnings per share (EPS) for the quarter. Research analysts forecast that BiondVax Pharmaceuticals will post -0.02 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in BiondVax Pharmaceuticals stock. Envestnet Asset Management Inc. grew its holdings in BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXVGet Rating) by 226.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 163,423 shares of the company’s stock after acquiring an additional 113,418 shares during the period. Envestnet Asset Management Inc. owned 1.44% of BiondVax Pharmaceuticals worth $191,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 2.94% of the company’s stock.

About BiondVax Pharmaceuticals

(Get Rating)

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.

Featured Stories

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.